Dual checkpoint T(h1)eamwork makes the anti-cancer dream work.
Immunity
; 57(3): 406-408, 2024 Mar 12.
Article
em En
| MEDLINE
| ID: mdl-38479356
ABSTRACT
Combined anti-PD-L1+anti-CTLA-4 therapy has shown benefits over anti-PD-L1 monotherapy as a neoadjuvant treatment in head and neck cancer. In this issue of Immunity, Franken et al. report that CD4+ T cell trafficking from lymph nodes to tumors and expansion toward T helper 1 cells are features specific to combination therapy.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias de Cabeça e Pescoço
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article